EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieMultizentrische Studie

A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis

Thomas L Abell iD, Braden Kuo, Tuba Esfandyari, Nathan D Pfeifer, Maria Grimaldi, Cecilia Renzulli, Raffaella Tacchi, Kefei Zhou, Chris N Barnes, Deanna D Nguyen iD, Linda Nguyen iD, Nicholas J Talley iD and 1 more

Neurogastroenterology & Motility · 2023

DOI: 10.1111/nmo.14523 ↗

At a glance

Randomisierte kontrollierte Studie in Neurogastroenterology & Motility, 2023. Written by Thomas L Abell and 12 co-authors. Institution: University of Louisville, Louisville, Kentucky, USA. Major MEDLINE topics: Gastroparesis, Diabetes Mellitus. Cited 17 times so far (Crossref); 42 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

This study assessed the efficacy and safety of velusetrag—a 5‐HT 4 agonist with pan‐gastrointestinal prokinetic activity—for gastroparesis symptom management and gastric emptying (GE).

Methods

In this multicenter, double‐blind, randomized, placebo‐controlled study, subjects with diabetic or idiopathic gastroparesis received velusetrag 5, 15, or 30 mg or placebo for 12 weeks. The primary efficacy outcome was a 7‐day mean Gastroparesis Cardinal Symptom Index 24‐h composite score (GCSI‐24H) change from baseline at week 4; GE was evaluated using scintigraphy (GES) and breath tests, and safety from adverse events (AEs). Key Results 232 subjects (183 females; 113 idiopathic gastroparesis) received treatment from February 2015 through June 2017. Least‐squares mean improvement from baseline GCSI‐24H (primary endpoint) at week 4 was −1.5 following velusetrag 5 mg vs −1.1 following placebo (treatment difference, −0.4; 95% confidence interval, −0.75 to −0.03; nominal p = 0.0327; Hochberg‐adjusted p = 0.0980 [not significant]). Symptom improvement from baseline was achieved only with velusetrag 5 mg, which resulted in greater improvement from baseline vs placebo in all gastroparesis core symptoms, especially in subjects with idiopathic gastroparesis. Improvement from baseline GE by GES was greater in subjects receiving velusetrag (all doses) vs placebo; >70% of subjects receiving velusetrag 30 mg had GE normalization at 4 h. Treatment‐emergent AEs were generally mild. Conclusions and Inferences Velusetrag treatment was generally well‐tolerated and associated with improved GE vs placebo in subjects with diabetic or idiopathic gastroparesis; however, only the lowest dose, velusetrag 5 mg, was associated with short‐term improvement in gastroparesis symptoms. ClinicalTrials .gov NCT02267525.

Subjects

MeSH terms (MEDLINE)

GastroparesisDiabetes MellitusFemaleHumansGastric EmptyingDouble-Blind MethodTreatment OutcomeAzabicyclo Compounds

Author keywords

5-HT4 receptor agonistGCSI-24Hgastric emptyinggastroparesispatient-reported outcomesvelusetrag

Substances

TD-5108Azabicyclo Compounds

Authors and institutions

  • University of Louisville, Louisville, Kentucky, USA.
  • Massachusetts General Hospital, Boston, Massachusetts, USA.
  • University of Kansas Medical School, Kansas City, Kansas, USA.
  • Theravance Biopharma US, Inc., South San Francisco, California, USA.
  • Alfasigma S.p.A, Bologna, Italy.
  • Stanford University School of Medicine, Stanford, California, USA.

ORCID profiles: Thomas L Abell, Deanna D Nguyen, Linda Nguyen, Nicholas J Talley, Richard McCallum

Cite

APA

Abell, T. L., Kuo, B., Esfandyari, T., Pfeifer, N. D., Grimaldi, M., Renzulli, C., Tacchi, R., Zhou, K., Barnes, C. N., Nguyen, D. D., Nguyen, L., Talley, N. J., & McCallum, R. (2023). A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.14523

Vancouver

Abell TL, Kuo B, Esfandyari T, Pfeifer ND, Grimaldi M, Renzulli C, et al. A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis. Neurogastroenterology & Motility. 2023. doi:10.1111/nmo.14523

BibTeX
@article{Abell2023,
  author = {Abell, Thomas L and Kuo, Braden and Esfandyari, Tuba and Pfeifer, Nathan D and Grimaldi, Maria and Renzulli, Cecilia and Tacchi, Raffaella and Zhou, Kefei and Barnes, Chris N and Nguyen, Deanna D and Nguyen, Linda and Talley, Nicholas J and McCallum, Richard},
  title = {A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis},
  journal = {Neurogastroenterology & Motility},
  year = {2023},
  doi = {10.1111/nmo.14523}
}
Start for free →